XJPX
4531
Market cap38mUSD
Jul 29, Last price
266.00JPY
1D
0.38%
1Q
5.56%
Jan 2017
4.72%
Name
Yuki Gosei Kogyo Co Ltd
Chart & Performance
Profile
Yuki Gosei Kogyo Co., Ltd. researches, develops, manufactures, and markets fine chemical products in Japan and internationally. It offers food additives, pharmaceuticals, and industrial and agricultural chemicals; and glycine, glycine compounds, nicotinic acid amide, isoniazid, drug intermediates, and cosmetic ingredients. The company also provides amino acid, pyridine, piperidine, silicon, and other compounds; DNA, nucleoside, and protamine; and active pharmaceutical ingredients. In addition, it engages in the contract manufacturing of pharmaceuticals and chemical products. Yuki Gosei Kogyo Co., Ltd. was founded in 1947 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
Income | |||||||||
Revenues | 12,932,000 0.72% | 12,839,000 3.87% | |||||||
Cost of revenue | 11,736,000 | 10,676,000 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,196,000 | 2,163,000 | |||||||
NOPBT Margin | 9.25% | 16.85% | |||||||
Operating Taxes | 129,000 | 84,000 | |||||||
Tax Rate | 10.79% | 3.88% | |||||||
NOPAT | 1,067,000 | 2,079,000 | |||||||
Net income | 776,000 39.57% | 556,000 124.19% | |||||||
Dividends | (152,000) | (87,000) | |||||||
Dividend yield | 2.20% | 1.34% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 4,629,000 | 4,436,000 | |||||||
Long-term debt | 2,594,000 | 1,584,000 | |||||||
Deferred revenue | 373,000 | 1,087,000 | |||||||
Other long-term liabilities | 1,486,000 | 6,000 | |||||||
Net debt | 4,510,000 | 3,123,000 | |||||||
Cash flow | |||||||||
Cash from operating activities | 388,000 | 668,000 | |||||||
CAPEX | (1,834,000) | (1,158,000) | |||||||
Cash from investing activities | (1,894,000) | (1,237,000) | |||||||
Cash from financing activities | 948,000 | (158,000) | |||||||
FCF | (1,662,000) | 818,000 | |||||||
Balance | |||||||||
Cash | 588,000 | 1,143,000 | |||||||
Long term investments | 2,125,000 | 1,754,000 | |||||||
Excess cash | 2,066,400 | 2,255,050 | |||||||
Stockholders' equity | 6,009,000 | 8,597,000 | |||||||
Invested Capital | 18,344,600 | 15,791,950 | |||||||
ROIC | 6.25% | 13.72% | |||||||
ROCE | 5.69% | 11.60% | |||||||
EV | |||||||||
Common stock shares outstanding | 21,824 | 21,824 | |||||||
Price | 317.00 6.73% | 297.00 8.39% | |||||||
Market cap | 6,918,080 6.73% | 6,481,857 8.39% | |||||||
EV | 11,428,080 | 9,604,857 | |||||||
EBITDA | 2,125,000 | 3,091,000 | |||||||
EV/EBITDA | 5.38 | 3.11 | |||||||
Interest | 49,000 | 50,000 | |||||||
Interest/NOPBT | 4.10% | 2.31% |